tg-c

Cell therapyexperimental

Clinical trial activity

4 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0

Earliest trial started Sep 16, 2018 (NCT03291470)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2025

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetTissue restoration

    tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06144970Phase 1Nov 1, 2025TissueGene, Inc.
NCT05276011Phase 2Oct 31, 2023TissueGene, Inc.
NCT03203330Phase 3Sep 16, 2018The Cleveland Clinic, TissueGene, Inc.
NCT03291470Phase 3Sep 16, 2018Commonwealth Orthopedics, TissueGene, Inc.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TissueGene, Inc.For profit4432018
Commonwealth OrthopedicsAcademic/Hospital1012018
The Cleveland ClinicAcademic/Hospital1012018
3 organizations
Page 1 / 1